Skip to main content

Table 2 Summary of studies analyzing the impact of ART on HPV incidence, persistence and clearance among HIV-infected women

From: RTehvieew impact of antiretroviral therapy on HPV andcervical intraepithelial neoplasia: current evidence and directions for future research

Author Outcome Follow-up Results Comparison and reference groups Association (95% CI), p value Conclusion
Lillo et al 2001 HPV PCR biannually Outcome: Incidence or Persistence (same HPV genotype at enrollment and follow-up) Median 15.4 months Incidence: HAART vs. no therapy
Persistence: HAART vs. no therapy
OR 0.28 (0.09-0.86), p 0.02
OR 1.18, (0.37-3.77), p 0.77
HAART protective against new HPV infections
No impact of HAART on persistence
Del Mistro et al 2004 HPV PCR every 6-12 months Outcome: Persistence and Clearance (undefined) 49% of N followed for >3 years No odds ratios discussed -- "Prevalence and clearance of HPV not associated with HAART"
Paramsothy et al 2009 HPV PCR every 6 months for 10 visits, then annually Outcome: HPV Clearance (2 negative HPV PCR tests at consecutive visits) Median 2 years for women on HAART; 2.7 years not on HAART HAART vs. no HAART (adjusted for CD4+ counts)
(i) in women with LSIL or HSIL
(ii) in women with ASCUS on cytology
(iii) in women with normal cytology
(i) HR 4.5 (95% CI: 1.2 16.3)
(ii) HR 1.0 (95% CI: 0.4-2.5)
(iii) HR 1.7 (95% CI: 0.9-3.1)
HAART promoted clearance of HPV infection in women with LSIL or HSIL on cytology.
No impact of HAART on women with ASCUS cytology No impact of HAART on women with normal cytology